oracle i RAMPED as you call last week and we eventually got to 30% one post today and we are down.look at it how you want and if it makes you happy SHHHHHH just merely bring a air of confidence and attacking a new angle as board was dying
Your senseless and uninformative ramping does more damage then good. For if ramping was the way to go, we would all be doing it. I guess you seem to gain some form of intimacy or emotional satisfaction so I'll allow it.
Food for thought, as you say regarding the funding i would have thought this was all thought through a while ago in anticipation of positive results. Sareum would not have wanted have wanted to hold progress up. Just my thoughts GLA.
This might also explain some of the silence recently.
Its just a guess but it wouldn't suprise me if we had confirmation that the IND application to start trials was announced at the same time that we are told how it will be funded and (for once) this might not be through a placing
Whilst we are still not sure on the reason for the rise last week, there is one piece of info that came to light just before it started to go up and it hasn’t really been discussed since NUM4 spotted it (thank you). It could be a coincidence, but I don’t think so.
The Events section on the website has been updated and Tim will be attending On Helix next month. In this, Tim is chairing a discussion with the National Institute of Health Research, the Wellcome Trust (both of which provide funding for trials – e.g. WT have given SUMM up to £4m for their phase 1 /2 clinical trials) and investors. So far, the confirmed attendees are: Welcome Trust, Syncoma Partners (WT’s investment arm), NIHR (added over the weekend) and SROne (GSK’s Venture Capital arm). Full details are here:
I guess the question is why did On Helix ask Tim to chair the discussion? On the face of it, he has had lots of fundraising experience, but mainly through placements and the SEDA (with just the £150k TSB grant for FASN coming from elsewhere). None of these companies have provided funds (yet) and I’m not sure why Tim would be asked. It just seems like an odd choice to me. Almost cruel, as Tim needs money and they have it.
FYI, this isn’t the first time SAR has been linked with the Wellcome Trust. See here for an old post from Phytochrome (which also has some good links for research on CHK1).
We know that the CHK1 trials will cost more (estimated at £1.3m similar to BACITs share) and I thought that a placing was the most likely source for this (based on past events) however after looking into the attendees of this meeting I’m starting to think differently.
Tim doesn’t need the money right now and won’t until the clinical trials application is submitted - you need to prove you can pay for it before they approve the trials and the application won’t be submitted until all of the pre-clinical data is gathered to support it (which has already cost SAR £800k in addition to the above). But last thing you want is to get to IND application stage without the funds to pay for the trials as this would delay the application, which is something I’m sure SARs partners do not want and they already have the funds in place.
Does anyone else think it’s possible (likely?) that Tim has secured funds from an alternative route (i.e. a Wellcome Trust grant for a few million to pay for Phase 1 and 2 trials similar to SUMM)? If he has, there would be no need to issue an RNS now, because until the pre-clinical work is finished and the IND goes in, this funding might not be needed. It would be agreed in principle at this stage and would only come into force once the IND was ready to go. This also might expl
This sat at 1p for prety much all pf 2013. Now the ftse100 is picking up it womt be lomg before aim does too. I have a feeling we will be back to 1p in the next couple of weeks. Then ready for news. I have a good feeling even short term traders will earn a few quid here. Wouldnt want to miss that chance. Its coming sareums. Hold onto those seats.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.